Opelconazole

Opelconazole
Clinical data
Other names	PC-945
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 4-[4-[4-[[(3R,5R)-5-(2,4-Difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]-3-methylphenyl]piperazin-1-yl]-N-(4-fluorophenyl)benzamide;
CAS Number	1931946-73-4;
PubChem CID	121383526;
UNII	45LU8Q6ASU;
Chemical and physical data
Formula	C38H37F3N6O3
Molar mass	682.748 g·mol−1

Opelconazole (PC-945) is an experimental antifungal drug and the first triazole delivered via inhalation.^[1]^[2]^[3] The drug is in Phase III and Phase II trials as of 2023.^[4]

References[edit]

^ Wiederhold, Nathan P. (August 2022). "Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents". Journal of Fungi. 8 (8): 857. doi:10.3390/jof8080857. ISSN 2309-608X. PMC 9410397. PMID 36012845.
^ Neoh, Chin Fen; Jeong, Wirawan; Kong, David CM; Slavin, Monica A (3 June 2023). "The antifungal pipeline for invasive fungal diseases: what does the future hold?". Expert Review of Anti-infective Therapy. 21 (6): 577–594. doi:10.1080/14787210.2023.2203383. PMID 37057677. S2CID 258135111.
^ Ito, Kazuhiro (2022). "Inhaled antifungal therapy: benefits, challenges, and clinical applications". Expert Opinion on Drug Delivery. 19 (7): 755–769. doi:10.1080/17425247.2022.2084530. PMID 35634895.
^ "Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole". BioSpace. Retrieved 4 November 2023.

This medical article is a stub. You can help Wikipedia by expanding it.

[1] Wiederhold, Nathan P. (August 2022). "Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents". Journal of Fungi. 8 (8): 857. doi:10.3390/jof8080857. ISSN 2309-608X. PMC 9410397. PMID 36012845.

[2] Neoh, Chin Fen; Jeong, Wirawan; Kong, David CM; Slavin, Monica A (3 June 2023). "The antifungal pipeline for invasive fungal diseases: what does the future hold?". Expert Review of Anti-infective Therapy. 21 (6): 577–594. doi:10.1080/14787210.2023.2203383. PMID 37057677. S2CID 258135111.

[3] Ito, Kazuhiro (2022). "Inhaled antifungal therapy: benefits, challenges, and clinical applications". Expert Opinion on Drug Delivery. 19 (7): 755–769. doi:10.1080/17425247.2022.2084530. PMID 35634895.

[4] "Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole". BioSpace. Retrieved 4 November 2023.

[1]

[2]

[3]

[4]